Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Second Act for Third-Party Pharma Auditing Anticipated

This article was originally published in The Gold Sheet

Executive Summary

FDA officials are looking at using the Food Safety Modernization Act as a model in developing a third-party review program for globally sourced drug products and ingredients. The recently enacted legislation would allow private third parties as well as foreign governments to conduct food safety inspections on behalf of FDA.

You may also be interested in...



User Fee Bill Puts Industry, U.S. FDA to Work On Global Supply Chain Risks

The user fee legislation U.S. Congress approved June 26 makes quality risk management a GMP requirement, further pressuring pharmaceutical manufacturers to make sure they are protecting their global supply chains.

User Fee Bill Puts Industry, FDA to Work on Supply Chain Risks

The user fee legislation Congress approved June 26 makes quality risk management a GMP requirement, further pressuring pharmaceutical manufacturers to make sure they are protecting their global supply chains. The bill directs FDA to inspect based on risk rather than time or location, and to rely on trusted foreign inspectorates, while adding new user fees for generic drugs that will boost funding for further expansion of the agency’s inspectorate.

FDA Considers Using Third-Party Inspectors to Enhance Global Reach

FDA is talking about adding an outsourced inspectorate to help it police the globally outsourced pharmaceutical manufacturing industry.

UsernamePublicRestriction

Register

PS000598

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel